Stockscreener 앱 받기
62.58
1.35%
-0.855
전일 마감가:
$63.44
열려 있는:
$63.87
하루 거래량:
1.23M
Relative Volume:
0.64
시가총액:
$7.65B
수익:
$18.47M
순이익/손실:
$-589.53M
주가수익비율:
-11.90
EPS:
-5.26
순현금흐름:
$-399.80M
1주 성능:
+0.11%
1개월 성능:
+0.90%
6개월 성능:
+61.79%
1년 성능:
+33.18%
1일 변동 폭
$62.17
$65.35
1주일 범위
$60.30
$65.35
52주 변동 폭
$29.31
$70.98
Cytokinetics Inc Stock (CYTK) Company Profile
명칭
Cytokinetics Inc
전화
(650) 624-3000
주소
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
CYTK을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
62.58 | 7.76B | 18.47M | -589.53M | -399.80M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-18 | 업그레이드 | Goldman | Neutral → Buy |
| 2025-07-30 | 재개 | Raymond James | Mkt Perform |
| 2025-04-24 | 개시 | Barclays | Overweight |
| 2025-02-07 | 개시 | Citigroup | Buy |
| 2025-01-22 | 개시 | Stifel | Buy |
| 2024-11-08 | 개시 | RBC Capital Mkts | Outperform |
| 2024-08-13 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-01-24 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-01-05 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-09 | 개시 | Goldman | Buy |
| 2023-11-07 | 개시 | B. Riley Securities | Buy |
| 2023-08-15 | 개시 | SVB Securities | Outperform |
| 2023-02-17 | 개시 | BofA Securities | Neutral |
| 2022-12-23 | 재확인 | Needham | Buy |
| 2022-12-20 | 개시 | Truist | Buy |
| 2022-10-11 | 개시 | UBS | Buy |
| 2022-01-28 | 개시 | Goldman | Buy |
| 2021-12-22 | 개시 | Oppenheimer | Outperform |
| 2021-12-10 | 개시 | JP Morgan | Overweight |
| 2021-10-07 | 개시 | Jefferies | Buy |
| 2021-03-12 | 개시 | Wolfe Research | Outperform |
| 2021-02-18 | 개시 | Barclays | Overweight |
| 2021-01-20 | 재확인 | H.C. Wainwright | Buy |
| 2020-10-29 | 개시 | Goldman | Neutral |
| 2020-07-10 | 개시 | Raymond James | Strong Buy |
| 2020-05-05 | 개시 | Mizuho | Buy |
| 2020-04-09 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-09-10 | 재개 | Morgan Stanley | Equal-Weight |
| 2017-11-22 | 재확인 | Morgan Stanley | Overweight |
| 2017-11-22 | 다운그레이드 | Needham | Strong Buy → Buy |
| 2017-11-21 | 재확인 | H.C. Wainwright | Buy |
| 2017-07-31 | 개시 | Morgan Stanley | Overweight |
| 2017-03-08 | 개시 | Rodman & Renshaw | Buy |
| 2017-02-06 | 업그레이드 | Needham | Buy → Strong Buy |
| 2016-12-16 | 개시 | Cantor Fitzgerald | Overweight |
| 2016-07-28 | 재확인 | Needham | Buy |
| 2015-11-10 | 재확인 | FBR Capital | Outperform |
| 2015-11-09 | 재확인 | ROTH Capital | Buy |
| 2015-07-24 | 재확인 | MLV & Co | Buy |
| 2014-12-31 | 재확인 | ROTH Capital | Buy |
| 2014-11-04 | 업그레이드 | MLV & Co | Hold → Buy |
| 2014-04-28 | 재확인 | Needham | Buy |
모두보기
Cytokinetics Inc 주식(CYTK)의 최신 뉴스
Should you avoid Cytokinetics Incorporated stock right now2025 Risk Factors & Stepwise Trade Signal Guides - baoquankhu1.vn
Profit Recap: Is TCBX in accumulation or distribution phaseWeekly Market Summary & Safe Swing Trade Setup Alerts - baoquankhu1.vn
Spinal Muscular Atrophy Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Genentech Inc, Chugai Pharma, Cytokinetics Inc., Ionis Pharma, Genzyme - Barchart.com
Orsini Selected as Specialty Pharmacy Partner for Cytokinetics's MYQORZO™ (aficamten) - PR Newswire
SG Americas Securities LLC Purchases 43,349 Shares of Cytokinetics, Incorporated $CYTK - MarketBeat
Cytokinetics, Incorporated (CYTK) Stock Analysis: A Biotech With 41% Upside Potential - DirectorsTalk Interviews
Cytokinetics, Incorporated (NASDAQ:CYTK) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
FDA approves seven NMEs in December - biocentury.com
Jefferies raises Cytokinetics stock price target to $90 on ACACIA study - Investing.com Canada
How Cytokinetics Incorporated stock trades before earnings2025 Volume Leaders & Momentum Based Trading Ideas - ulpravda.ru
Is Cytokinetics Incorporated stock attractive for long term wealth building2025 Institutional Moves & High Accuracy Trade Alerts - ulpravda.ru
Is Cytokinetics Incorporated stock attractive for hedge fundsQuarterly Portfolio Summary & Safe Entry Trade Reports - ulpravda.ru
Is Cytokinetics Incorporated stock a good choice for value investorsWeekly Investment Report & Step-by-Step Swing Trade Plans - ulpravda.ru
Is Cytokinetics Incorporated (KK3A) stock a top pick for value investorsQuarterly Trade Summary & Daily Growth Stock Investment Tips - ulpravda.ru
Can Cytokinetics Incorporated stock deliver consistent earnings growthPortfolio Value Summary & Risk Controlled Stock Alerts - ulpravda.ru
What makes Cytokinetics Incorporated stock attractive to growth fundsIPO Watch & AI Based Trade Execution Alerts - ulpravda.ru
Risk Analysis: Can Cytokinetics Incorporated stock reach $100 price targetMarket Performance Recap & Expert Curated Trade Ideas - ulpravda.ru
Can Cytokinetics Incorporated stock maintain growth trajectoryInsider Selling & Daily Profit Focused Screening - ulpravda.ru
Cytokinetics, Incorporated (CYTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Important Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Lifecore ... - Bluefield Daily Telegraph
Important Notice to Long-Term Shareholders of Cytokinetics, - GlobeNewswire
Press Telegram - FinancialContent
How Aficamten REMS Disclosure Probe Will Impact Cytokinetics (CYTK) Investors - Yahoo Finance
HC Wainwright & Co. maintains Cytokinetics (CYTK) buy recommendation - MSN
Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Lifecore Biomedical, ... - Bluefield Daily Telegraph
Notice to Long-Term Shareholders of Cytokinetics, Inc. - GlobeNewswire
Insider Sell: Andrew Callos Sells 15,000 Shares of Cytokinetics Inc (CYTK) - GuruFocus
Cytokinetics (NASDAQ:CYTK) EVP Sells $904,200.00 in Stock - MarketBeat
Cytokinetics Executive Sells 15,000 Shares - TradingView — Track All Markets
Cytokinetics to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Tango Therapeutics Appoints Sung Lee to Board of Directors - GlobeNewswire Inc.
Cytokinetics (NASDAQ:CYTK) EVP Sells $112,590.76 in Stock - MarketBeat
Callos, Cytokinetics EVP, sells $112,584 in stock By Investing.com - Investing.com South Africa
Callos, Cytokinetics EVP, sells $112,584 in stock - Investing.com India
Cytokinetics (CYTK) stock closes up 3.5% into year-end as Myqorzo launch nears, insider sale disclosed - ts2.tech
Cytokinetics, Incorporated (CYTK) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Cytokinetics, Incorporated (CYTK) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Cytokinetics (CYTK) stock ends 2025 higher as Myqorzo launch nears — what’s next - ts2.tech
Moody Aldrich Partners LLC Buys Shares of 82,460 Cytokinetics, Incorporated $CYTK - MarketBeat
Cytokinetics Stock Soars: What’s Next? - StocksToTrade
Cytokinetics stock jumps today as CYTK traders focus on Myqorzo launch and insider filing - ts2.tech
Cytokinetics (NASDAQ:CYTK) Trading 3% HigherStill a Buy? - MarketBeat
The Year-End 2025 Biotech Rally And What It Means For 2026 - Benzinga
Top Cytokinetics Insider Just Cashed Out in a High-Profile Stock Move - TipRanks
Insider Sell: Andrew Callos Sells Shares of Cytokinetics Inc (CY - GuruFocus
Cytokinetics (NASDAQ:CYTK) EVP Andrew Callos Sells 1,809 Shares of Stock - MarketBeat
Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Molina Healthcare, Inc. ... - Bluefield Daily Telegraph
Notice to Long-Term Shareholders of Alexandria Real Estate - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Encourages Cytokinetics, Incorporated (CYTK) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Cytokinetics, Incorporated (CYTK) And Encourages Shareholders to Connect - ACCESS Newswire
What Does the Market Think About Cytokinetics Inc? - Benzinga
Cytokinetics Inc (CYTK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Cytokinetics Inc 주식 (CYTK) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Callos Andrew | EVP, Chief Commercial Officer |
Jan 05 '26 |
Sale |
60.28 |
15,000 |
904,200 |
50,440 |
| Callos Andrew | EVP, Chief Commercial Officer |
Jan 02 '26 |
Option Exercise |
37.63 |
885 |
33,303 |
51,325 |
| Callos Andrew | EVP, Chief Commercial Officer |
Jan 02 '26 |
Sale |
62.62 |
1,798 |
112,585 |
50,440 |
4.73%
0.92%
자본화:
|
볼륨(24시간):